MA27490A1 - Formulation d'ibuprofene sodique. - Google Patents

Formulation d'ibuprofene sodique.

Info

Publication number
MA27490A1
MA27490A1 MA28268A MA28268A MA27490A1 MA 27490 A1 MA27490 A1 MA 27490A1 MA 28268 A MA28268 A MA 28268A MA 28268 A MA28268 A MA 28268A MA 27490 A1 MA27490 A1 MA 27490A1
Authority
MA
Morocco
Prior art keywords
weight
sodium hydrate
tablet
ibuprofen
coating
Prior art date
Application number
MA28268A
Other languages
English (en)
Inventor
Gruber Peter
Reher Markus
Original Assignee
Bayer Consumer Care Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28796671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27490(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Consumer Care Ag filed Critical Bayer Consumer Care Ag
Publication of MA27490A1 publication Critical patent/MA27490A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Comprimé non effervescent d'ibuprofène. comprenant un comprimé nu et, si on le souhaite, une dragéification ou un pelliculage, dans lequel le comprimé nu se compose de 50 à 100% en poids d'hydrate d'ibuprofène sodique et de 50 à 0% en poids d'adjuvant, sur la base du poids du comprimé nu. et ne contient ni lubrifiant ni agent de délitement, l'hydrate d'ibuprofène sodique ayant une teneur en eau allant de 8 à 16%, de préference de 11 à 16% en poids, qui possède une dureté suffisante, qui est d'une taille relativement petite et mène à une augmentation particulièrement rapide des concentrations sanguines et, par conséquence, a un début accéléré de l'effet analgésique. Contrairement à l'opinion reçue, l'hydrate d'ibuprofène sodique ayant une teneur en eau appropriée est suffisamment compressible.
MA28268A 2002-10-14 2005-05-09 Formulation d'ibuprofene sodique. MA27490A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH01703/02A CH693586A8 (de) 2002-10-14 2002-10-14 Darreichungsform von Ibuprofen-Natrium.

Publications (1)

Publication Number Publication Date
MA27490A1 true MA27490A1 (fr) 2005-08-01

Family

ID=28796671

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28268A MA27490A1 (fr) 2002-10-14 2005-05-09 Formulation d'ibuprofene sodique.

Country Status (32)

Country Link
US (1) US20040102522A1 (fr)
EP (1) EP1410793B1 (fr)
JP (1) JP4608316B2 (fr)
KR (1) KR101046894B1 (fr)
CN (1) CN100592909C (fr)
AR (1) AR041428A1 (fr)
AT (1) ATE309789T1 (fr)
AU (1) AU2003266094B2 (fr)
BR (1) BRPI0315248B1 (fr)
CA (1) CA2500987A1 (fr)
CH (1) CH693586A8 (fr)
CO (1) CO5700709A2 (fr)
DE (1) DE50301661D1 (fr)
DK (1) DK1410793T3 (fr)
EA (1) EA007914B1 (fr)
EC (1) ECSP055793A (fr)
ES (1) ES2249702T3 (fr)
HR (1) HRP20050429A2 (fr)
IL (1) IL167357A (fr)
MA (1) MA27490A1 (fr)
MX (1) MXPA05003592A (fr)
MY (1) MY132858A (fr)
NO (1) NO20052343L (fr)
NZ (1) NZ539405A (fr)
PA (1) PA8586101A1 (fr)
PE (1) PE20040417A1 (fr)
PL (1) PL376177A1 (fr)
SI (1) SI1410793T1 (fr)
TW (1) TWI262800B (fr)
UA (1) UA86751C2 (fr)
WO (1) WO2004035024A1 (fr)
ZA (1) ZA200502925B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6705028B2 (en) * 2001-09-12 2004-03-16 Honda Giken Kogyo Kabushiki Kaisha Self-propelled snowplow vehicle
US20050176809A1 (en) * 2004-02-05 2005-08-11 Rodlen Laboratories, Inc. Method and compositions for treatment of painful disorders
KR101482922B1 (ko) * 2004-08-12 2015-01-15 레킷트 벵키저 헬스케어(유케이)리미티드 용융 압출에 의해 제조된, ｎｓａｉｄ와 당 알콜을 포함하는 과립
US20070077297A1 (en) 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
WO2006093353A1 (fr) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Composition a liberation controlee
RU2403033C2 (ru) 2005-03-22 2010-11-10 Лозан Фарма Гмбх Солюбилизированный ибупрофен
EP1800667A1 (fr) 2005-12-23 2007-06-27 Losan Pharma GmbH Granulate d'ibuprofen solubilisé rapidement
DE102006029233A1 (de) * 2006-06-26 2007-12-27 Liedtke, Rainer K., Dr. Formulierungen zur Verbesserung der Verträglichkeit nichtsteroidaler Antiphlogistika
CL2007002425A1 (es) * 2006-08-22 2008-06-27 Albermarle Corp Procedimiento de preparacion controlado de sal sodica de ibuprofeno de tamano de particula mediano; y dichas particulas de sal sodica.
FI20080348A0 (fi) * 2008-02-15 2008-05-09 Atacama Labs Oy Uudenlainen farmaseuttinen formulaatio
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
US9629809B2 (en) 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
EP2309988B1 (fr) * 2008-07-21 2015-11-25 SI Group, Inc. Granulés d'ibuprofène sodique à teneur, leur préparation et leur utilisation dans la préparation de formes posologiques solides non effervescentes
US20110144207A1 (en) * 2008-08-14 2011-06-16 Shasun Chemicals And Drugs Limited Aryl alkyl carboxylic acid salts, process for preparation and dosage forms
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
AU2014200704C1 (en) * 2009-06-22 2018-12-06 Pf Consumer Healthcare 1 Llc Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen
AU2015264861C1 (en) * 2009-06-22 2017-11-16 Pf Consumer Healthcare 1 Llc Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen
TWI542344B (zh) * 2009-06-22 2016-07-21 惠氏有限責任公司 異丁苯丙酸鈉錠及製備包含異丁苯丙酸鈉之醫藥組合物之方法
FR2997856B1 (fr) * 2012-11-14 2015-04-24 Pf Medicament Pastille medicamenteuse a base d'ibuprofene sodique dihydrate
EP2965746B1 (fr) 2014-07-10 2019-03-13 Santa Farma Ilaç Sanayi A.S. Composition pharmaceutique orale comprenant de l'ibuprofène, du dihydrate de sodium d'ibuprofène, de l'hydrochlorure de pseudoéphédrine et du maléate de chlorophéniramine
US20180078516A1 (en) * 2016-09-19 2018-03-22 Innovazone Labs LLC Pharmaceutical Composition of Ibuprofen Sodium for Oral Administration
CN113893227B (zh) * 2021-11-18 2023-04-14 山东则正医药技术有限公司 布洛芬片的制备原料、制备方法和布洛芬片
CN119488489A (zh) * 2024-11-29 2025-02-21 华中药业股份有限公司 一种布洛芬片及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5104648A (en) * 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US4911921A (en) * 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
GB8920693D0 (en) * 1989-09-13 1989-10-25 Nicholas Kiwi Pty Ltd Non-effervescent ibuprofen compositions
CA2061520C (fr) * 1991-03-27 2003-04-22 Lawrence J. Daher Systeme de delivrance accelerant l'effet et accroissant la puissance
GB9224021D0 (en) * 1992-11-16 1993-01-06 Boots Co Plc Effervescent compositions
US6083430A (en) * 1994-10-28 2000-07-04 Fuisz Technologies Ltd. Method of preparing a dosage unit by direct tableting and product therefrom
GB9603699D0 (en) * 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
IT1301966B1 (it) * 1998-07-30 2000-07-20 Zambon Spa Composizioni farmaceutiche ad attivita' analgesica

Also Published As

Publication number Publication date
US20040102522A1 (en) 2004-05-27
PA8586101A1 (es) 2005-05-10
JP4608316B2 (ja) 2011-01-12
WO2004035024A1 (fr) 2004-04-29
SI1410793T1 (sl) 2006-04-30
TW200407175A (en) 2004-05-16
DE50301661D1 (de) 2005-12-22
CO5700709A2 (es) 2006-11-30
MY132858A (en) 2007-10-31
HRP20050429A2 (en) 2005-06-30
MXPA05003592A (es) 2005-09-30
UA86751C2 (ru) 2009-05-25
ZA200502925B (en) 2006-02-22
ECSP055793A (es) 2005-08-11
CH693586A5 (de) 2003-10-31
BR0315248A (pt) 2005-08-23
CN100592909C (zh) 2010-03-03
CA2500987A1 (fr) 2004-04-29
AU2003266094B2 (en) 2009-04-23
EA007914B1 (ru) 2007-02-27
DK1410793T3 (da) 2006-04-03
AU2003266094A1 (en) 2004-05-04
CH693586A8 (de) 2003-12-15
ATE309789T1 (de) 2005-12-15
KR101046894B1 (ko) 2011-07-06
CN1705470A (zh) 2005-12-07
PL376177A1 (en) 2005-12-27
IL167357A (en) 2009-05-04
EP1410793B1 (fr) 2005-11-16
ES2249702T3 (es) 2006-04-01
JP2006505558A (ja) 2006-02-16
NZ539405A (en) 2006-12-22
NO20052343L (no) 2005-06-02
EA200500649A1 (ru) 2005-10-27
PE20040417A1 (es) 2004-07-14
EP1410793A1 (fr) 2004-04-21
AR041428A1 (es) 2005-05-18
KR20050083760A (ko) 2005-08-26
TWI262800B (en) 2006-10-01
BRPI0315248B1 (pt) 2016-08-02

Similar Documents

Publication Publication Date Title
EA200500649A1 (ru) Форма дозировки натриевой соли ибупрофена
WO2004089353A3 (fr) Procedes de traitement de la maladie de parkinson
EP2260850A3 (fr) Antagonistes des récepteurs A2A pour utilisation dans le traitement des troubles du mouvement
CA2473201A1 (fr) Composition pharmaceutique orodispersible d'agomelatine
TW200505357A (en) Novel glycopeptides and peptide with imparting rich taste and its method of imparting rich taste to food
MY148121A (en) Sesamin / episesamin compositions
TR200002894T2 (tr) L-Karnitin veya bir alkanoil L-Karnitin ve NADH ve/veya NADPH içeren kompozisyon
WO2004018044A8 (fr) Usage therapeutique
EP1572086A4 (fr) Methodes et composition basees sur la decouverte d'un metabolisme de la nitroglycerine
DK1613571T3 (da) Deutererede catecholaminderivater og lægemidler indeholdende disse forbidelser
EA200801305A1 (ru) Применение циклетанина и других фуропиридинов для лечения гипертензии с преобладанием систолического давления, изолированной систолической гипертензии, повышенного пульсового артериального давления и общей гипертензии
FR2865011B1 (fr) Cuve notamment destinee au traitement sous pression d'objets
ES2486844T3 (es) Sustancia que presenta propiedad antidepresiva
TW200738255A (en) Methods of regulating renalase (Monoamine Oxidase C)
GB2431347A (en) Peripherally-acting vasodilators
WO2006058298A3 (fr) Procede d'administration d'agents anti-angiogeniques, et methode de traitement d'une maladie utilisant lesdits agents
MXPA03010921A (es) Uso de acetil l-carnitina en asociacion con biotina para tratamiento der pacientes con diabetes mellitus resistente a insulina tipo 2.
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
Kajander et al. Coronary artery disease modifies left ventricular remodelling due to heavy alcohol consumption
AR044009A1 (es) Combinacion farmaceutica que comprende eletriptan y bicarbonato de sodio
RU2002131671A (ru) Средство, повышающее резистентность организма в постгипотермическом периоде
Choi et al. Reality and the subject of Korea Game Education
RU2005112335A (ru) Биологически активная добавка к пище
RU2002110993A (ru) Пищевая биологически активная добавка "Энерголам плюс"
RU2002109127A (ru) Капли Макарова-Соловьева